|
US5981562A
(en)
*
|
1996-01-30 |
1999-11-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US5968965A
(en)
*
|
1996-01-30 |
1999-10-19 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
JP2000504017A
(ja)
*
|
1996-01-30 |
2000-04-04 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシル―タンパク質転移酵素の阻害剤
|
|
JP2000504014A
(ja)
*
|
1996-01-30 |
2000-04-04 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシル―タンパク質転移酵素の阻害剤
|
|
US6028201A
(en)
*
|
1996-01-30 |
2000-02-22 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US6300501B1
(en)
|
1996-05-22 |
2001-10-09 |
Warner-Lambert Company |
Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
|
|
US6265382B1
(en)
*
|
1997-04-11 |
2001-07-24 |
Warner-Lambert Company |
Dipeptide inhibitors of protein farnesyltransferase
|
|
US6737410B1
(en)
|
1997-04-11 |
2004-05-18 |
Warner-Lambert Company |
Inhibitors of protein farnesyl transferase
|
|
US20030069231A1
(en)
|
1999-10-12 |
2003-04-10 |
Klaus Rudolf |
Modified aminoacids, pharmaceuticals containing these compounds and method for their production
|
|
AU759492B2
(en)
*
|
1998-04-27 |
2003-04-17 |
Warner-Lambert Company |
Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
|
|
WO2000034437A2
(en)
|
1998-12-08 |
2000-06-15 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
AU2478500A
(en)
|
1998-12-08 |
2000-06-26 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
US6632818B2
(en)
|
2000-01-12 |
2003-10-14 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
JP2002188646A
(ja)
*
|
2000-12-20 |
2002-07-05 |
Nsk Ltd |
転がり軸受及び軸受装置
|
|
US7595312B2
(en)
|
2002-10-25 |
2009-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
|
|
WO2005049589A2
(en)
*
|
2003-10-14 |
2005-06-02 |
Cadila Healthcare Limited |
Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
|
|
DE102004015723A1
(de)
|
2004-03-29 |
2005-10-20 |
Boehringer Ingelheim Pharma |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
EP1888050B1
(en)
|
2005-05-17 |
2012-03-21 |
Merck Sharp & Dohme Ltd. |
cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
|
|
PE20070427A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
|
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
PL2010528T3
(pl)
|
2006-04-19 |
2018-03-30 |
Novartis Ag |
6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
|
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
EP2805945B1
(en)
|
2007-01-10 |
2019-04-03 |
MSD Italia S.r.l. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
|
ES2431163T3
(es)
|
2007-03-01 |
2013-11-25 |
Novartis Ag |
Inhibidores de PIM quinasa y métodos para su uso
|
|
ES2452349T3
(es)
|
2007-05-21 |
2014-04-01 |
Novartis Ag |
Inhibidores de CSF-1R, composiciones, y métodos de uso
|
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
|
WO2010144909A1
(en)
|
2009-06-12 |
2010-12-16 |
Novartis Ag |
Fused heterocyclic compounds and their uses
|
|
EP2488028B1
(en)
|
2009-10-14 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
|
CN103080093A
(zh)
|
2010-03-16 |
2013-05-01 |
达纳－法伯癌症研究所公司 |
吲唑化合物及其应用
|
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
CN107090456B
(zh)
|
2010-08-02 |
2022-01-18 |
瑟纳治疗公司 |
使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
|
|
JP2013537423A
(ja)
|
2010-08-17 |
2013-10-03 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
EP2699568A1
(en)
|
2011-04-21 |
2014-02-26 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
CA2856291C
(en)
|
2011-11-17 |
2020-08-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
|
EP2844261B1
(en)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
CN105050598B
(zh)
|
2012-09-28 |
2018-04-27 |
默沙东公司 |
作为erk抑制剂的新型化合物
|
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
RS56680B1
(sr)
|
2012-11-28 |
2018-03-30 |
Merck Sharp & Dohme |
Kompozicije i postupci za lečenje kancera
|
|
US8846657B2
(en)
|
2012-12-20 |
2014-09-30 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
AU2014337122B2
(en)
|
2013-10-18 |
2019-01-03 |
Dana-Farber Cancer Institute, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
|
US10047070B2
(en)
|
2013-10-18 |
2018-08-14 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
|
EP3236959B1
(en)
|
2014-12-23 |
2025-09-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
US10702527B2
(en)
|
2015-06-12 |
2020-07-07 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
|
US10975084B2
(en)
|
2016-10-12 |
2021-04-13 |
Merck Sharp & Dohme Corp. |
KDM5 inhibitors
|
|
MX2019012233A
(es)
|
2017-04-13 |
2020-01-14 |
Aduro Biotech Holdings Europe Bv |
Anticuerpos anti-sirpa.
|
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
US11098059B2
(en)
|
2017-11-08 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
JP7590185B2
(ja)
|
2018-06-25 |
2024-11-26 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
|
|
CA3108388A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
EP3833668B1
(en)
|
2018-08-07 |
2025-03-19 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
WO2020033285A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
AU2019413694B2
(en)
|
2018-12-28 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 and uses thereof
|
|
EP4076460B1
(en)
|
2019-12-17 |
2026-01-21 |
Merck Sharp & Dohme LLC |
1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
|
|
WO2024180169A1
(en)
|
2023-03-02 |
2024-09-06 |
Carcimun Biotech Gmbh |
Means and methods for diagnosing cancer and/or an acute inflammatory disease
|
|
WO2026027944A1
(en)
|
2024-07-30 |
2026-02-05 |
Sairopa B.V. |
Anti-sirp alpha antibody formulations and uses thereof
|